Is Cyclacel Pharmaceuticals Stock a Good Investment?
Cyclacel Pharmaceuticals Investment Advice | CYCC |
- Examine Cyclacel Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Cyclacel Pharmaceuticals' leadership team and their track record. Good management can help Cyclacel Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Cyclacel Pharmaceuticals' business and its evolving consumer preferences.
- Compare Cyclacel Pharmaceuticals' performance and market position to its competitors. Analyze how Cyclacel Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Cyclacel Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Cyclacel Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Cyclacel Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Cyclacel Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves totally opposite to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Cyclacel Pharmaceuticals Stock
Researching Cyclacel Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 18.0% of the company shares are held by institutions such as insurance companies. The book value of Cyclacel Pharmaceuticals was currently reported as 0.57. The company recorded a loss per share of 27.4. Cyclacel Pharmaceuticals last dividend was issued on the 15th of April 2020. The entity had 1:15 split on the 18th of December 2023.
To determine if Cyclacel Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cyclacel Pharmaceuticals' research are outlined below:
| Cyclacel Pharmaceuticals generated a negative expected return over the last 90 days | |
| Cyclacel Pharmaceuticals has high historical volatility and very poor performance | |
| Cyclacel Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Cyclacel Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 420 K. Net Loss for the year was (22.55 M) with profit before overhead, payroll, taxes, and interest of 80 K. | |
| Cyclacel Pharmaceuticals currently holds about 29.08 M in cash with (16.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cyclacel Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Cyclacel Pharmaceuticals Research Coverage Started at StockNews.com |
Cyclacel Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Cyclacel Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cyclacel Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cyclacel Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Cyclacel Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Cyclacel Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-08-09 | 2023-06-30 | -0.5 | -0.44 | 0.06 | 12 | ||
2021-08-11 | 2021-06-30 | -0.5 | -0.56 | -0.06 | 12 | ||
2020-11-11 | 2020-09-30 | -0.55 | -0.47 | 0.08 | 14 | ||
2022-03-28 | 2021-12-31 | -0.65 | -0.54 | 0.11 | 16 | ||
2021-11-10 | 2021-09-30 | -0.65 | -0.54 | 0.11 | 16 | ||
2020-08-12 | 2020-06-30 | -0.47 | -0.58 | -0.11 | 23 | ||
2023-03-06 | 2022-12-31 | -0.48 | -0.6 | -0.12 | 25 | ||
2023-11-13 | 2023-09-30 | -0.36 | -0.49 | -0.13 | 36 |
Know Cyclacel Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cyclacel Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cyclacel Pharmaceuticals backward and forwards among themselves. Cyclacel Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Cyclacel Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2024-09-30 | 15.0 | Harbour Investments, Inc. | 2024-09-30 | 13.0 | Acadian Asset Management Llc | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Renaissance Technologies Corp | 2024-06-30 | 0.0 | Qube Research & Technologies | 2024-09-30 | 0.0 | Hrt Financial Llc | 2024-09-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 145 K | Point72 Asset Management, L.p. | 2024-09-30 | 15.3 K | Ubs Group Ag | 2024-09-30 | 12.6 K | Geode Capital Management, Llc | 2024-09-30 | 10.6 K |
Cyclacel Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.03 M.Market Cap |
|
Cyclacel Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.95) | (2.80) | |
| Return On Capital Employed | (45.45) | (43.18) | |
| Return On Assets | (2.95) | (2.80) | |
| Return On Equity | (42.73) | (40.60) |
Determining Cyclacel Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Cyclacel Pharmaceuticals is a good buy. For example, gross profit margin measures Cyclacel Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cyclacel Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Cyclacel Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cyclacel Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Cyclacel Pharmaceuticals' management manipulating its earnings.
Evaluate Cyclacel Pharmaceuticals' management efficiency
Cyclacel Pharmaceuticals has return on total asset (ROA) of (1.0253) % which means that it has lost $1.0253 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.7069) %, meaning that it created substantial loss on money invested by shareholders. Cyclacel Pharmaceuticals' management efficiency ratios could be used to measure how well Cyclacel Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -2.8. The current year's Return On Capital Employed is expected to grow to -43.18. At present, Cyclacel Pharmaceuticals' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 23.9 M, whereas Total Assets are forecasted to decline to about 7.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.64 | 0.67 | |
| Tangible Book Value Per Share | 0.64 | 0.67 | |
| Enterprise Value Over EBITDA | 0.04 | 0.04 | |
| Price Book Value Ratio | 3.37 | 3.54 | |
| Enterprise Value Multiple | 0.04 | 0.04 | |
| Price Fair Value | 3.37 | 3.54 | |
| Enterprise Value | -1.2 M | -1.2 M |
Cyclacel Pharmaceuticals showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta 0.557 |
Basic technical analysis of Cyclacel Stock
As of the 1st of February, Cyclacel Pharmaceuticals shows the risk adjusted performance of (0.12), and Mean Deviation of 5.29. Cyclacel Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Cyclacel Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cyclacel Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cyclacel Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cyclacel Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cyclacel Pharmaceuticals' Outstanding Corporate Bonds
Cyclacel Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cyclacel Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cyclacel bonds can be classified according to their maturity, which is the date when Cyclacel Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Cyclacel Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Cyclacel Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | 0.8653 | |||
| Mean Deviation | 5.29 | |||
| Coefficient Of Variation | (671.41) | |||
| Standard Deviation | 7.21 | |||
| Variance | 51.97 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.97) | |||
| Total Risk Alpha | (1.86) | |||
| Treynor Ratio | 0.8553 | |||
| Maximum Drawdown | 33.21 | |||
| Value At Risk | (13.33) | |||
| Potential Upside | 9.76 | |||
| Skewness | 0.5835 | |||
| Kurtosis | 2.09 |
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | 0.8653 | |||
| Mean Deviation | 5.29 | |||
| Coefficient Of Variation | (671.41) | |||
| Standard Deviation | 7.21 | |||
| Variance | 51.97 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.97) | |||
| Total Risk Alpha | (1.86) | |||
| Treynor Ratio | 0.8553 | |||
| Maximum Drawdown | 33.21 | |||
| Value At Risk | (13.33) | |||
| Potential Upside | 9.76 | |||
| Skewness | 0.5835 | |||
| Kurtosis | 2.09 |
Consider Cyclacel Pharmaceuticals' intraday indicators
Cyclacel Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cyclacel Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Cyclacel Pharmaceuticals time-series forecasting models is one of many Cyclacel Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cyclacel Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Cyclacel Stock media impact
Far too much social signal, news, headlines, and media speculation about Cyclacel Pharmaceuticals that are available to investors today. That information is available publicly through Cyclacel media outlets and privately through word of mouth or via Cyclacel internal channels. However, regardless of the origin, that massive amount of Cyclacel data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cyclacel Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cyclacel Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cyclacel Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cyclacel Pharmaceuticals alpha.
Cyclacel Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Cyclacel Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
When determining whether Cyclacel Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclacel Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclacel Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclacel Pharmaceuticals Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (27.40) | Revenue Per Share | Quarterly Revenue Growth (0.99) | Return On Assets | Return On Equity |
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Cyclacel Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Cyclacel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.